Biotech Values

[DewDiligence]

AVTE IPOs 9.98M* shares @$14.00:

https://www.globenewswire.com/news-release/2021/06/30/2255267/0/en/Aerovate-Therapeutics-Announces-Pricing-of-Upsized-Initial-Public-Offering.html

Aerovate [Therapeutics] is a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. Aerovate's initial focus is on advancing AV-101, its dry powder inhaled formulation of the drug imatinib for the treatment of pulmonary arterial hypertension, or PAH.

Imatinib is generic Gleevec.

*Assuming exercise of underwriter’s option.